Patients with Newly Diagnosed Hypertension Treated with Azilsartan Medoxomil vs. Angiotensin-converting Enzyme Inhibitors: The Prospective EARLY Registry


eMediNexus    02 January 2018

Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) constitute the first-line therapies for patients with newly diagnosed hypertension. The prospective registry, Treatment with Azilsartan Compared to ACE Inhibitors in Antihypertensive Therapy (EARLY), assessed the effectiveness of the ARB azilsartan medoxomil (AZL-M) vs. ACE inhibitors in real-world patients. Out of 1153 patients with newly diagnosed hypertension included in the registry, 789 were prescribed azilsartan and 364 were prescribed an ACE inhibitor. Following multivariate adjustment, azilsartan was noted to yield superior blood pressure (BP) reduction and better target BP (<140/90 mm Hg) achievement. The proportion of patients with adverse events was not statistically different between groups. Researchers concluded that in newly diagnosed hypertensive patients, azilsartan provides superior BP control with a similar safety profile compared with ACE inhibitors. The findings are published in the Journal of Clinical Hypertension (Greenwich).

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.